Recent publication showed there are significant peanut proteins in household dust.
But what is the relevance of this study, and how does it apply to the development of allergies?
The best course of action to deal with eczema, and potentially prevent the development of allergies, should be:
(In due course, I will publish more information regarding eczema and the best way to take care of it.)
(Main article – “Mass spectrometry confirmation that clinically important peanut protein allergens are in household dust”; Helen A. Brough, Elizabeth Naomi Clare Mills, Kerry Richards, Gideon Lack, Philip E. Johnson; 04 October 2019)
The incidence of peanut allergy has been increasing significantly in developed countries.
Many reasons have been found for such growth, but so far no proper treatment has been found to deal with it.
Often, antihistamines are the first choice when there is an allergic reaction, with the occasional need to use adrenaline as well.
Most of the symptoms start in childhood and persists throughout life.
Due to this, the search for ways to deal with this specific allergy is ongoing, though not matching current needs.
As such, today, I will focus on a promising medication that might lead to a significant change in the way we deal with peanut, and possibly, tree nut
On a Phase 2a randomized placebo control trial, running for six weeks, a single injection of Etokimab showed that it could desensitize peanut allergic adults.
They concluded that it could potentially desensitize peanut-allergic participants and possibly reduce atopy-related adverse events.
I understand the first part, but what is the connection to atopy?
Let me explain.
Can you see me coming again to the top priority of maintaining the skin barrier to prevent allergy?
My opinion about it:
How does it compare to the current two available oral peanut immunotherapy?
CA002 (Cambridge) and AR101 (London)
Michael R. Perkin, Consultant Paediatric Allergist PhD, wrote that the major concern regarding this immunotherapy is that 𝐚𝐥𝐥𝐞𝐫𝐠𝐞𝐧 𝐭𝐨𝐥𝐞𝐫𝐚𝐧𝐜𝐞 𝐭𝐡𝐚𝐭 𝐢𝐬 𝐢𝐧𝐝𝐮𝐜𝐞𝐝 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐭𝐞𝐦𝐩𝐨𝐫𝐚𝐫𝐲, 𝐚𝐧𝐝 𝐥𝐨𝐬𝐭 𝐢𝐟 𝐫𝐞𝐠𝐮𝐥𝐚𝐫 𝐜𝐨𝐧𝐬𝐮𝐦𝐩𝐭𝐢𝐨𝐧 𝐜𝐞𝐚𝐬𝐞𝐬.
Neither groups have attempted to establish the duration for which allergen tolerance is maintained in the absence of ongoing consumption, potentially lifelong, 𝐫𝐞𝐠𝐮𝐥𝐚𝐫 𝐜𝐨𝐧𝐬𝐮𝐦𝐩𝐭𝐢𝐨𝐧 𝐦𝐚𝐲 𝐛𝐞 𝐧𝐞𝐞𝐝𝐞𝐝 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐚𝐥𝐥𝐞𝐫𝐠𝐞𝐧 𝐭𝐨𝐥𝐞𝐫𝐚𝐧𝐜𝐞.
𝐓𝐡𝐢𝐬 𝐦𝐞𝐚𝐧𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐨𝐮𝐥𝐝 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐭𝐚𝐤𝐞 𝐭𝐡𝐞 𝐦𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐚 𝐝𝐚𝐢𝐥𝐲 𝐛𝐚𝐬𝐢𝐬 𝐨𝐫 𝐭𝐡𝐞𝐫𝐞 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐫𝐞𝐯𝐞𝐫𝐬𝐚𝐥 𝐨𝐟 𝐬𝐲𝐦𝐩𝐭𝐨𝐦𝐬. 𝐀𝐧𝐝 𝐭𝐡𝐢𝐬 𝐰𝐚𝐬 𝐚𝐥𝐫𝐞𝐚𝐝𝐲 𝐩𝐫𝐨𝐯𝐞𝐧 𝐢𝐧 𝐚 𝐫𝐞𝐜𝐞𝐧𝐭 𝐬𝐭𝐮𝐝𝐲.
To consider that AR101 will cost between $5000 to $10,000 for the first six months of use, and $300 to $400 per month after that.
Dr Costa is a Consultant Paediatrician and fellow of the Royal College of Paediatrics and Child Health.